경증 및 중등도 본태성 고혈압 환자에서 Candesartan Cilexetil의 강압효과 및 임상적 안전성에 대한 연구.

Abstract

Background and Objectives : Candesartan cilexetil (Atacand ), a selective type I angiotensin II receptor blocker, has recently been introduced as a new antihypertensive agent. We evaluated its anti-hypertensive effect and safety in mild to moderate hypertensive patients.

Materials and Methods : Candesartan cilexetil, 8 mg or 16 mg, was administered once a day over 8 weeks period in the patients with mild to moderate hypertension (25 male, 26 female, mean age: 53.5±1.2 years). For safety evaluation, laboratory tests were performed before and after treatment with candesartan cilexetil. Changes in blood pressure, heart rate and electrocardiogram were also observed.

Results : 1) The mean blood pressures in the sitting position were systolic 164.1±2.1 mmHg and diastolic 106.3±0.8 mmHg before treatment, which were lowered to 135.4±2.0 mmHg and 89.1±1.1 mmHg, repectively after 8 weeks of treatment (p<0.05). 2) Candesartan cilexetil had a significant dose-depen-dent antihypertensive effect for diastolic pressure in 35 patients (8 mg:97.8±0.9 mmHg, 16 mg:91.3±1.1 mmHg, p<0.05). 3) Heart rate was not significantly changed before and after treatment during the treatment with candesartan cilexetil (72.2±1.2/min vs. 72.0±1.3/min;p>0.05). 4) Laboratory tests revealed no significant abnormality by the treatment with candesartan cilexetil. 5) Left ventricular hypertrophy by ECG criteria detected in 3 cases disappeared after treatment with candesartan cilexetil. 6) No significant side effects were observed during the treatment period.

Conclusion : Candesartan cilexetil, 8 mg or 16 mg, once a day is an effective and well tolerated antihypertensive treatment. It has a significant dose-dependent antihypertensive effect.